Cargando…
The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080321/ https://www.ncbi.nlm.nih.gov/pubmed/37033344 http://dx.doi.org/10.21037/tcr-22-2843 |
| _version_ | 1785020896851787776 |
|---|---|
| author | Denault, Marie-Helene Ho, Cheryl |
| author_facet | Denault, Marie-Helene Ho, Cheryl |
| author_sort | Denault, Marie-Helene |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10080321 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100803212023-04-08 The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management Denault, Marie-Helene Ho, Cheryl Transl Cancer Res Editorial Commentary AME Publishing Company 2023-02-23 2023-03-31 /pmc/articles/PMC10080321/ /pubmed/37033344 http://dx.doi.org/10.21037/tcr-22-2843 Text en 2023 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Denault, Marie-Helene Ho, Cheryl The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management |
| title | The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management |
| title_full | The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management |
| title_fullStr | The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management |
| title_full_unstemmed | The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management |
| title_short | The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management |
| title_sort | benefit of the doubt: pd-l1 status in unresectable stage iii nsclc management |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080321/ https://www.ncbi.nlm.nih.gov/pubmed/37033344 http://dx.doi.org/10.21037/tcr-22-2843 |
| work_keys_str_mv | AT denaultmariehelene thebenefitofthedoubtpdl1statusinunresectablestageiiinsclcmanagement AT hocheryl thebenefitofthedoubtpdl1statusinunresectablestageiiinsclcmanagement AT denaultmariehelene benefitofthedoubtpdl1statusinunresectablestageiiinsclcmanagement AT hocheryl benefitofthedoubtpdl1statusinunresectablestageiiinsclcmanagement |